Prevalence of type 2 diabetes in Middle-East: Systematic review& meta-analysis. 2020

K H Kalan Farmanfarma, and A Ansari-Moghaddam, and I Zareban, and H A Adineh
Department of Public Health, School of Health, Zahedan University of Medical Sciences, Zahedan, Iran.

Type 2 diabetes is increasing in both developed and developing countries due to popularity of western lifestyle and population structure. Then, this systematic review aimed to identify the prevalence and trend of diabetes in the Middle-East region. We searched Google Scholar, PubMed and Medline from 2000 up to 2018. MeSH terms were a combination of "diabetes", "prevalence", "diabetes mellitus", "type 2 diabetes", "Name of Countries" and "Middle East". Pooled estimates were obtained by means of random effect models to account for variation between studies. Of the initially 669 identified articles, a total of 50 reports with 4,263,662 subjects met inclusion criteria. The combined prevalence of diabetes in the region was about 14.6% (95% CI: 11.6-17.5) which varied from 2.6% (95% CI: 2.5-2.6) to 21.9 (95% CI: 16.8-17.5) amongst countries. Therefore, approximately a total of 46 million individuals are now suffering from diabetes in the Middle East based on above-mentioned pooled estimate. The pattern and growing trend of diabetes during last 20 years in the study area is alarming and underline the point that maximal risk reduction for developing diabetes should be at the top of health priorities.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008877 Middle East The region of southwest Asia and northeastern Africa usually considered as extending from Libya on the west to Afghanistan on the east. (From Webster's New Geographical Dictionary, 1988) Gaza Strip,Near East,West Bank,Gaza Strip (Palestine)
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

K H Kalan Farmanfarma, and A Ansari-Moghaddam, and I Zareban, and H A Adineh
January 2022, Healthcare (Basel, Switzerland),
K H Kalan Farmanfarma, and A Ansari-Moghaddam, and I Zareban, and H A Adineh
June 2023, Pathogens and global health,
K H Kalan Farmanfarma, and A Ansari-Moghaddam, and I Zareban, and H A Adineh
January 2021, Frontiers in reproductive health,
K H Kalan Farmanfarma, and A Ansari-Moghaddam, and I Zareban, and H A Adineh
November 2023, Diabetes & metabolic syndrome,
K H Kalan Farmanfarma, and A Ansari-Moghaddam, and I Zareban, and H A Adineh
May 2021, International journal of environmental research and public health,
K H Kalan Farmanfarma, and A Ansari-Moghaddam, and I Zareban, and H A Adineh
September 2015, Iranian journal of psychiatry,
K H Kalan Farmanfarma, and A Ansari-Moghaddam, and I Zareban, and H A Adineh
June 2020, International ophthalmology,
K H Kalan Farmanfarma, and A Ansari-Moghaddam, and I Zareban, and H A Adineh
May 2018, The clinical respiratory journal,
K H Kalan Farmanfarma, and A Ansari-Moghaddam, and I Zareban, and H A Adineh
January 2022, PloS one,
Copied contents to your clipboard!